[[Translated article]]Pruritus in Dermatology: Part 2 - Diseases and Their Treatment.

[1]  S. Vieths,et al.  An update on anaphylaxis and urticaria. , 2022, The Journal of allergy and clinical immunology.

[2]  G. Yosipovitch,et al.  Lichen Simplex Chronicus Itch: An Update , 2022, Acta dermato-venereologica.

[3]  L. Wong,et al.  Chronic Nodular Prurigo: An Update on the Pathogenesis and Treatment , 2022, International journal of molecular sciences.

[4]  A. Pink,et al.  Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments , 2022, Dermatology and Therapy.

[5]  K. Takamori,et al.  Treatment Options for Troublesome Itch , 2022, Pharmaceuticals.

[6]  M. Gyldenløve,et al.  Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy , 2022, The British journal of dermatology.

[7]  L. Wong,et al.  Autoimmune Connective Tissue Diseases-Related Pruritus: Proper Diagnosis and Possible Mechanisms , 2022, Diagnostics.

[8]  X. Dou,et al.  Successful treatment of refractory prurigo nodularis with baricitinib , 2022, Dermatologic therapy.

[9]  S. Ständer,et al.  Pruritus bei atopischer Dermatitis – vergleichende Bewertung neuer Therapieansätze , 2022, Die Dermatologie.

[10]  M. Gyldenløve,et al.  Rapid clearing of refractory nummular dermatitis with oral roflumilast therapy , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  I. Narita,et al.  Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis , 2022, JAMA network open.

[12]  M. D. de Bruin‐Weller,et al.  Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis , 2022, American Journal of Clinical Dermatology.

[13]  T. Robak,et al.  Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives , 2022, Journal of clinical medicine.

[14]  S. Ständer,et al.  Pruritus in Pregnancy , 2022, American Journal of Clinical Dermatology.

[15]  E. Serra-Baldrich,et al.  Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis. , 2021, Actas dermo-sifiliograficas.

[16]  S. Ständer,et al.  Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open‐label extension phase , 2021, Journal of the European Academy of Dermatology and Venereology : JEADV.

[17]  Chao Ji,et al.  Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid , 2021, Frontiers in Immunology.

[18]  H. Saeki,et al.  Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized double-blind vehicle-controlled trial. , 2021, Journal of the American Academy of Dermatology.

[19]  G. Yosipovitch,et al.  Pruritus in Keloid Scars: Mechanisms and Treatments , 2021, Acta dermato-venereologica.

[20]  L. Misery,et al.  Clinical characteristics of itch in cutaneous lupus erythematosus: A prospective, multicenter, multinational, cross-sectional study , 2021, Lupus.

[21]  B. Strober,et al.  Bimekizumab versus Secukinumab in Plaque Psoriasis. , 2021, The New England journal of medicine.

[22]  U. Beuers,et al.  Cholestasis-Associated Pruritus and Its Pruritogens , 2021, Frontiers in Medicine.

[23]  Linghong Guo,et al.  Benefits and harms of NK1R antagonists in pruritus: A systematic review and meta‐analysis , 2020, Dermatologic therapy.

[24]  M. Polymeropoulos,et al.  Neurokinin‐1 receptor antagonist tradipitant has mixed effects on itch in atopic dermatitis: results from EPIONE, a randomized clinical trial , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[25]  J. Aneiros-Fernández,et al.  Histological Changes Related to Symptomatic Improvement of Spontaneous Keloids Treated with a Low-Dosage Regimen of UVA-1 Phototherapy , 2020, Dermatopathology.

[26]  M. Steinhoff,et al.  Interleukin‐31: The “itchy” cytokine in inflammation and therapy , 2020, Allergy.

[27]  K. Phan,et al.  Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis , 2020, The Journal of dermatological treatment.

[28]  Jiajing Zhou,et al.  Effectiveness of montelukast for uremic pruritus in hemodialysis patients , 2020, Medicine.

[29]  K. Takamori,et al.  Molecular and Cellular Mechanisms of Itch in Psoriasis , 2020, International journal of molecular sciences.

[30]  J. Meng,et al.  Novel Insights into the TRPV3-Mediated Itch in Atopic Dermatitis. , 2020, The Journal of allergy and clinical immunology.

[31]  A. Leung,et al.  Pityriasis Rosea: An Updated Review. , 2020, Current pediatric reviews.

[32]  M. Lebwohl,et al.  Trial of Roflumilast Cream for Chronic Plaque Psoriasis. , 2020, The New England journal of medicine.

[33]  M. Kawashima,et al.  Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus. , 2020, The New England journal of medicine.

[34]  J. Sanches,et al.  Progression of mycosis fungoides after treatment with dupilumab: A case report , 2020, Dermatologic therapy.

[35]  T. Karaca,et al.  Small fiber neuropathy and related factors in patients with systemic lupus erythematosus; the results of cutaneous silent period and skin biopsy , 2020, Advances in Rheumatology.

[36]  S. Shirazian,et al.  CKD-Associated Pruritus: New Insights Into Diagnosis, Pathogenesis, and Management , 2020, Kidney international reports.

[37]  J. Paolini,et al.  Oncostatin M Induction of Monocyte Chemoattractant Protein 1 is Inhibited by Anti-oncostatin M Receptor Beta Monoclonal Antibody KPL-716 , 2020, Acta dermato-venereologica.

[38]  F. Wang,et al.  Evaluation of apremilast in chronic pruritus of unknown origin: A proof‐of‐concept, phase 2a, open‐label, single‐arm clinical trial , 2020, Health science reports.

[39]  A. Armstrong,et al.  Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis , 2020, JAMA dermatology.

[40]  T. Bieber,et al.  Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. , 2020, The New England journal of medicine.

[41]  N. Samalavicius,et al.  Intradermal 1% methylene blue injection for intractable idiopathic pruritus ani – a video vignette , 2020, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[42]  X. Mariette,et al.  Small fiber neuropathy in Sjögren syndrome: Comparison with other small fiber neuropathies , 2020, Muscle & nerve.

[43]  Wenjun Zheng,et al.  Molecular mechanisms underlying menthol binding and activation of TRPM8 ion channel , 2020, Nature Communications.

[44]  Zhou-Feng Chen,et al.  PAR2 mediates itch via TRPV3 signaling in keratinocytes. , 2020, The Journal of investigative dermatology.

[45]  G. Yosipovitch,et al.  Methotrexate in the Treatment of Chronic Itch in the Geriatric Population , 2020, Acta dermato-venereologica.

[46]  C. Zhong,et al.  Phototherapy for Itch. , 2020, Dermatologic clinics.

[47]  J. Krueger,et al.  Keloid lesions show increased IL‐4/IL‐13 signaling and respond to Th2‐targeting dupilumab therapy , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[48]  P. Gisondi,et al.  A systematic review of treatments for pityriasis lichenoides , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[49]  Xiaoqun Wang,et al.  MRGPRX4 is a bile acid receptor for human cholestatic itch , 2019, eLife.

[50]  Tito D. Tubog,et al.  Use of Nalbuphine for Treatment of Neuraxial Opioid-Induced Pruritus: A Systematic Review and Meta-Analysis. , 2019, AANA journal.

[51]  R. Singh,et al.  Naloxone and Maintenance Naltrexone as Novel and Effective Therapies for Immunotherapy-Induced Pruritus: A Case Report and Brief Literature Review. , 2019, Journal of oncology practice.

[52]  Jason K. Lee,et al.  Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. , 2019, The journal of allergy and clinical immunology. In practice.

[53]  F. Legat.  The Antipruritic Effect of Phototherapy , 2018, Front. Med..

[54]  L. Misery,et al.  Clinical Characteristics of Pruritus in Systemic Sclerosis Vary According to the Autoimmune Subtype. , 2018, Acta dermato-venereologica.

[55]  J. Guitart,et al.  Pruritus in Cutaneous T-Cell Lymphoma and Its Management. , 2018, Dermatologic clinics.

[56]  V. Brodszky,et al.  Association between quality of life and clinical characteristics in patients with morphea , 2018, Quality of Life Research.

[57]  M. Duvic,et al.  Inflammatory cytokines and peripheral mediators in the pathophysiology of pruritus in cutaneous T‐cell lymphoma , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[58]  J. Szepietowski,et al.  Aquagenic Pruritus in Polycythemia Vera: Clinical Characteristics. , 2018, Acta dermato-venereologica.

[59]  T. Zuberbier,et al.  Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria , 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[60]  L. Misery,et al.  Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[61]  H. Kozono,et al.  Post-marketing surveillance study of the safety and efficacy of nalfurafine hydrochloride (Remitch® capsules 2.5 μg) in 3,762 hemodialysis patients with intractable pruritus , 2018, International journal of nephrology and renovascular disease.

[62]  A. Gottlieb,et al.  Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension. , 2018, Acta dermato-venereologica.

[63]  P. V. D. van de Kerkhof,et al.  Use of oral antidepressants in patients with chronic pruritus: A systematic review , 2017, Journal of the American Academy of Dermatology.

[64]  A. Reich,et al.  Prevalence and Relevance of Pruritus in Pregnancy , 2017, BioMed research international.

[65]  S. Kwatra,et al.  Aprepitant for the Treatment of Chronic Refractory Pruritus , 2017, BioMed research international.

[66]  F. Niyonsaba,et al.  Antimicrobial peptides human LL-37 and β-defensin-3 modulate the expression of nerve elongation factors in human epidermal keratinocytes. , 2017, Journal of dermatological science.

[67]  T. Nagano,et al.  Aprepitant for refractory nivolumab-induced pruritus. , 2017, Lung cancer.

[68]  L. Misery,et al.  Itch and systemic sclerosis: frequency, clinical characteristics and consequences , 2017, The British journal of dermatology.

[69]  Jonathan R. Brestoff,et al.  Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch , 2017, Cell.

[70]  Y. Chan,et al.  Topical ketamine‐amitriptyline‐lidocaine for chronic pruritus: A retrospective study assessing efficacy and tolerability , 2017, Journal of the American Academy of Dermatology.

[71]  G. Wendelschafer‐Crabb,et al.  Small‐fibre neuropathy in a patient with dermatomyositis and severe scalp pruritus , 2017, The British journal of dermatology.

[72]  G. Yosipovitch,et al.  Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out? , 2016, Clinical Reviews in Allergy & Immunology.

[73]  S. Kwatra,et al.  Gabapentin and pregabalin for the treatment of chronic pruritus. , 2016, Journal of the American Academy of Dermatology.

[74]  J. Jimenez,et al.  A Review of the Efficacy of Thalidomide and Lenalidomide in the Treatment of Refractory Prurigo Nodularis , 2016, Dermatology and Therapy.

[75]  H. Matsuda,et al.  Intrathecal Minocycline Suppresses Itch-Related Behavior and Improves Dermatitis in a Mouse Model of Atopic Dermatitis. , 2016, Journal of Investigative Dermatology.

[76]  M. Swamiappan.  Anogenital Pruritus - An Overview. , 2016, Journal of clinical and diagnostic research : JCDR.

[77]  R. Swerlick,et al.  Azathioprine treatment of intractable pruritus: A retrospective review. , 2015, Journal of the American Academy of Dermatology.

[78]  M. Weiss,et al.  Paraneoplastic itch: an expert position statement from the Special Interest Group (SIG) of the International Forum on the Study of Itch (IFSI). , 2015, Acta dermato-venereologica.

[79]  J. Bousquet,et al.  Update on rupatadine in the management of allergic disorders , 2015, Allergy.

[80]  A. Webster,et al.  Interventions for itch in people with advanced chronic kidney disease , 2014 .

[81]  S. Vanner,et al.  Participation of interleukin 17A in neuroimmune interactions , 2014, Brain, Behavior, and Immunity.

[82]  M. Suárez-Fariñas,et al.  Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. , 2014, The Journal of allergy and clinical immunology.

[83]  U. Beuers,et al.  Advances in Pathogenesis and Management of Pruritus in Cholestasis , 2014, Digestive Diseases.

[84]  D. Ye,et al.  Serum levels of cytokines in systemic lupus erythematosus , 2014, Zeitschrift für Rheumatologie.

[85]  R. Swerlick,et al.  Practical guidelines for the use of steroid‐sparing agents in the treatment of chronic pruritus , 2013, Dermatologic therapy.

[86]  E. Simpson,et al.  The effects of treatment on itch in atopic dermatitis , 2013, Dermatologic therapy.

[87]  D. Currow,et al.  The role of ondansetron in the management of cholestatic or uremic pruritus--a systematic review. , 2012, Journal of pain and symptom management.

[88]  B. Poligone,et al.  Pruritus in cutaneous T-cell lymphoma: a review. , 2012, Journal of the American Academy of Dermatology.

[89]  Tomoko Mori,et al.  Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigo. , 2011, European journal of dermatology : EJD.

[90]  E. Ernst,et al.  Systematic review of topical capsaicin in the treatment of pruritus , 2010, International journal of dermatology.

[91]  Z. Massy,et al.  Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[92]  R. Kraft,et al.  Distinct patterns of brain activity evoked by histamine‐induced itch reveal an association with itch intensity and disease severity in atopic dermatitis , 2009, The British journal of dermatology.

[93]  Alexandru D. P. Papoiu,et al.  Itch characteristics in atopic dermatitis: results of a web‐based questionnaire , 2009, The British journal of dermatology.

[94]  A. Kaplan,et al.  Progress and Challenges in the Understanding of Chronic Urticaria , 2007, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[95]  K. Akazawa,et al.  Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. , 2006, Kidney international.

[96]  G. Yosipovitch,et al.  Butorphanol for treatment of intractable pruritus. , 2006, Journal of the American Academy of Dermatology.

[97]  E. Farhangi,et al.  Effect of oral naltrexone on pruritus in cholestatic patients. , 2006, World journal of gastroenterology.

[98]  S. Feldman,et al.  Pruritus in adult dermatomyositis , 2004, Clinical and experimental dermatology.

[99]  S. Iwata,et al.  Ebastine inhibits T cell migration, production of Th2‐type cytokines and proinflammatory cytokines , 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[100]  M. Vasko,et al.  Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C , 2003, Pain.

[101]  G. Yosipovitch,et al.  The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis , 2000, The British journal of dermatology.

[102]  S. Beissert,et al.  Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. , 1999, Journal of the American Academy of Dermatology.

[103]  R. Dummer,et al.  Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation. , 1993, Archives of dermatology.

[104]  P. Harrison.  Nalmefene and pruritus. , 1990, Journal of the American Academy of Dermatology.

[105]  E. Sausville,et al.  Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups. , 1988, Annals of internal medicine.

[106]  R. Selgas Gutiérrez,et al.  Pruritus in dialysis patients. Review and new perspectives. , 2022, Nefrologia.

[107]  M. Maurer,et al.  New treatments for chronic urticaria. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[108]  V. Leis-Dosil,et al.  Practical Management of Immunosuppressants in Dermatology. , 2018, Actas dermo-sifiliograficas.

[109]  R. LaMotte.  Allergic Contact Dermatitis: A Model of Inflammatory Itch and Pain in Human and Mouse. , 2016, Advances in experimental medicine and biology.

[110]  A. López-Pestaña,et al.  Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma. , 2014, Actas dermo-sifiliograficas.

[111]  L. K. Golightly,et al.  Second-Generation Antihistamines Actions and Efficacy in the Management of Allergic Disorders , 2012 .

[112]  S. Ständer,et al.  Drug-induced pruritus: a review. , 2009, Acta dermato-venereologica.

[113]  P. Rubegni,et al.  Sjögren's syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology. , 2004, Clinical and experimental rheumatology.